Johnson & Johnson and Varian Medical exited the cancer radiotherapy developer in an upsized initial public offering after $158m in funding.

Fusion Pharmaceuticals, a Canada-based cancer drug developer backed by pharmaceutical group Johnson & Johnson and medical device maker Varian Medical Systems, raised almost $213m when it went public on Friday. The initial public offering involved the company increasing the number of shares in the IPO from 8.35 million to 12.5 million and pricing them at…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.